JP2002503229A - 眼球の疾患を治療するとき硝子体液を液化するのに用いる眼科製剤の製造に対するヒアルロニダーゼの使用 - Google Patents
眼球の疾患を治療するとき硝子体液を液化するのに用いる眼科製剤の製造に対するヒアルロニダーゼの使用Info
- Publication number
- JP2002503229A JP2002503229A JP55071998A JP55071998A JP2002503229A JP 2002503229 A JP2002503229 A JP 2002503229A JP 55071998 A JP55071998 A JP 55071998A JP 55071998 A JP55071998 A JP 55071998A JP 2002503229 A JP2002503229 A JP 2002503229A
- Authority
- JP
- Japan
- Prior art keywords
- hyaluronidase
- vitreous
- use according
- eye
- injection
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Enzymes And Modification Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.眼球の疾患にかかりやすい個体を保護するのに用いる薬剤を製造するための グリコサミノグリカナーゼの使用。 2.眼球の疾患が増殖性糖尿病網膜症である請求の範囲1に記載の使用。 3.眼球の疾患が加齢関連の黄斑変性である請求の範囲1に記載の使用。 4.眼球の疾患が弱視である請求の範囲1に記載の使用。 5.眼球の疾患が色素性網膜炎である請求の範囲1に記載の使用。 6.眼球の疾患が黄斑孔である請求の範囲1に記載の使用。 7.眼球の疾患が黄斑滲出物である請求の範囲1に記載の使用。 8.眼球の疾患が嚢胞黄斑水腫である請求の範囲1に記載の使用。 9.グリコサミノグリカナーゼを、後部硝子体の剥離(PVD)を誘発する量の グリコサミノグリカナーゼを硝子体内に投与するために適応させる請求の範囲1 に記載の使用。 10.グリコサミノグリカナーゼがヒアルロニダーゼである請求の範囲1に記載 の使用。 11.ヒアルロニダーゼが、注射用に適応させた形態である請求の範囲10に記 載の使用。 12.ヒアルロニダーゼが、チメロサールを含有しない製剤の形態である請求の 範囲10に記載の使用。 13.ヒアルロニダーゼが、5〜200国際単位を投与するため適応させた形態 である請求の範囲10に記載の使用。 14.ヒアルロニダーゼが、75国際単位を越える量を投与するため適応させた 形態である請求の範囲10に記載の使用。 15.ヒアルロニダーゼが、15国際単位を超える量を投与するため適応させた 形態である請求の範囲10に記載の使用。 16.ヒアルロニダーゼが、1国際単位を超える量を投与するため適応させた形 態である請求の範囲10に記載の使用。 17.ヒアルロニダーゼが、複数回投与するため適応させた形態である請求の範 囲10に記載の使用。 18.ヒアルロニダーゼが、注射用に適応させた形態であり、硝子体内への単回 注射液が100:1より小さい注射物容積を有してい る請求の範囲10に記載の使用。 19.ヒアルロニダーゼが、10%SDS PAGE電気泳動法で測定したとき 約100,000より大きい分子量を有するヒアルロン酸溶解活性、10%SD S PAGE電気泳動法で測定したとき約60,000〜100,000の分子 量を有するゼラチン分解活性、および10%SDS PAGE電気泳動法で測定 したとき約45,000より大きい分子量を有するカゼイン分解活性を欠いてい る請求の範囲10に記載の使用。 20.ヒアルロニダーゼが、4〜20%SDS PAGE電気泳動法で測定した とき約100,000より大きい分子量を有するヒアルロニダーゼ体、4〜20 %SDS PAGE電気泳動法で測定したとき約50,000〜60,000の 分子量を有するヒアルロニダーゼ体、および4〜20%SDS PAGE電気泳 動法で測定したとき約20,000より小さい分子量を有するヒアルロニダーゼ 体を欠いている請求の範囲10に記載の使用。 21.ヒアルロニダーゼが、チメロサールを含有せずかつ配合が以下の配合: 8,000IUまでの前記ヒアルロニダーゼ、 5.0〜130.0mgのラクトース、および 0.01〜100.0mmolのリン酸塩 である注射用に適応させた液剤の形態である請求の範囲10に記載の使用。 22.ヒアルロニダーゼが、チメロサールを含有せずかつ配合が以 下の配合: 6,500IUの前記ヒアルロニダーゼ、 5.0mgのラクトース、および 0.02mmolのリン酸塩 である注射用に適応させた液剤の形態である請求の範囲10に記載の使用。 23.ヒアルロニダーゼが、チメロサールを含有せずかつ配合が以下の配合: 500〜1,000IUの前記ヒアルロニダーゼ、 5.0〜10.0mgのラクトース、および 0.01〜10.0mmolのリン酸塩 である注射用に適応させた液剤の形態である請求の範囲10に記載の使用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US86262097A | 1997-05-22 | 1997-05-22 | |
US08/862,620 | 1997-05-22 | ||
PCT/US1998/010578 WO1998052602A1 (en) | 1997-05-22 | 1998-05-22 | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2002503229A true JP2002503229A (ja) | 2002-01-29 |
JP4256941B2 JP4256941B2 (ja) | 2009-04-22 |
Family
ID=25338874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP55071998A Expired - Lifetime JP4256941B2 (ja) | 1997-05-22 | 1998-05-22 | 眼球の疾患の治療において硝子体液を液化するために使用されるヒアルロニダーゼ含有製剤 |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP0983084B1 (ja) |
JP (1) | JP4256941B2 (ja) |
KR (1) | KR100566451B1 (ja) |
CN (1) | CN1257430A (ja) |
AU (1) | AU7693698A (ja) |
BR (1) | BR9809558A (ja) |
CA (1) | CA2288622A1 (ja) |
DE (1) | DE69836858T2 (ja) |
DK (1) | DK0983084T3 (ja) |
ES (1) | ES2281128T3 (ja) |
PT (1) | PT983084E (ja) |
WO (1) | WO1998052602A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010029190A (ja) * | 2003-03-05 | 2010-02-12 | Halozyme Inc | 可溶性ヒアルロニダーゼ糖タンパク質(sHASEGP)、その調製プロセス、使用およびそれを含む薬学的組成物 |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69928087D1 (de) | 1998-03-09 | 2005-12-08 | Ista Pharmaceuticals Inc | Verwendung von glyceraldehyde als hornhaut härtungsmitteln |
US6335006B1 (en) | 1999-03-22 | 2002-01-01 | Boston Innovative Optics, Inc. | Methods of using agents that act on the epithelial sheet of a human eye |
DK1173198T3 (da) * | 1999-04-29 | 2004-04-13 | Ista Pharmaceuticals Inc | Anvendelse af en bestemt hyaluronidase til eliminering af ar på, uigennemsigtighed og uklarhed på hornhinden |
WO2001039795A2 (en) * | 1999-12-02 | 2001-06-07 | Ibex Technologies, Inc. | Attenuation of fibroblast proliferation |
GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
NZ588638A (en) | 2008-04-14 | 2012-09-28 | Halozyme Inc | Screening method for identifying a subject for treatment with a modified hyaluronidase polypeptides |
CN102266348A (zh) * | 2011-08-04 | 2011-12-07 | 山西诺成制药有限公司 | 一种眼内冲洗液及其制备方法 |
WO2021154969A1 (en) * | 2020-01-28 | 2021-08-05 | Standard Of Care Corporation | Hyaluronidase compositions and methods of using same to treat fibrosis |
CN111617313B (zh) * | 2020-04-29 | 2022-09-06 | 天津医科大学眼科医院 | 一种眼用线性凝胶在作为临床孔源性视网膜脱离药物方面中的应用 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ZA912770B (en) * | 1990-04-16 | 1992-01-29 | Bethesda Eye Inst | Enzymatic disinsertion of vitreous body |
US5866120A (en) * | 1995-11-22 | 1999-02-02 | Advanced Corneal Systems, Inc. | Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase |
-
1998
- 1998-05-22 BR BR9809558-7A patent/BR9809558A/pt not_active IP Right Cessation
- 1998-05-22 PT PT98924866T patent/PT983084E/pt unknown
- 1998-05-22 ES ES98924866T patent/ES2281128T3/es not_active Expired - Lifetime
- 1998-05-22 AU AU76936/98A patent/AU7693698A/en not_active Abandoned
- 1998-05-22 WO PCT/US1998/010578 patent/WO1998052602A1/en active IP Right Grant
- 1998-05-22 KR KR1019997010750A patent/KR100566451B1/ko not_active IP Right Cessation
- 1998-05-22 JP JP55071998A patent/JP4256941B2/ja not_active Expired - Lifetime
- 1998-05-22 EP EP98924866A patent/EP0983084B1/en not_active Expired - Lifetime
- 1998-05-22 CN CN98805342A patent/CN1257430A/zh active Pending
- 1998-05-22 CA CA002288622A patent/CA2288622A1/en not_active Abandoned
- 1998-05-22 DE DE69836858T patent/DE69836858T2/de not_active Expired - Lifetime
- 1998-05-22 DK DK98924866T patent/DK0983084T3/da active
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010029190A (ja) * | 2003-03-05 | 2010-02-12 | Halozyme Inc | 可溶性ヒアルロニダーゼ糖タンパク質(sHASEGP)、その調製プロセス、使用およびそれを含む薬学的組成物 |
JP2013031446A (ja) * | 2003-03-05 | 2013-02-14 | Halozyme Inc | 可溶性ヒアルロニダーゼ糖タンパク質(sHASEGP)、その調製プロセス、使用およびそれを含む薬学的組成物 |
US9562223B2 (en) | 2003-03-05 | 2017-02-07 | Halozyme, Inc. | Methods for reducing intraocular pressure by administering a soluble hyaluronidase glycoprotein (sHASEGP) |
US9677061B2 (en) | 2003-03-05 | 2017-06-13 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
US9677062B2 (en) | 2003-03-05 | 2017-06-13 | Halozyme, Inc. | Hyaluronidase and factor VIII compositions |
US10286044B2 (en) | 2003-03-05 | 2019-05-14 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
US10898551B2 (en) | 2003-03-05 | 2021-01-26 | Halozyme, Inc. | Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof |
US11723959B2 (en) | 2003-03-05 | 2023-08-15 | Halozyme, Inc. | Preparation of mammalian oocyte for fertilization via a soluble human PH20 hyaluronidase polypeptide |
Also Published As
Publication number | Publication date |
---|---|
EP0983084A1 (en) | 2000-03-08 |
CN1257430A (zh) | 2000-06-21 |
KR20010012787A (ko) | 2001-02-26 |
PT983084E (pt) | 2007-04-30 |
AU7693698A (en) | 1998-12-11 |
JP4256941B2 (ja) | 2009-04-22 |
DE69836858T2 (de) | 2007-09-06 |
WO1998052602A1 (en) | 1998-11-26 |
DK0983084T3 (da) | 2007-05-07 |
BR9809558A (pt) | 2000-07-04 |
ES2281128T3 (es) | 2007-09-16 |
DE69836858D1 (de) | 2007-02-22 |
EP0983084B1 (en) | 2007-01-10 |
KR100566451B1 (ko) | 2006-03-31 |
CA2288622A1 (en) | 1998-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6863886B2 (en) | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders | |
Bonnet | Serous macular detachment associated with optic nerve pits | |
Davis et al. | Optic nerve head drusen | |
US5866120A (en) | Method for accelerating clearance of hemorrhagic blood from the vitreous humor with hyaluronidase | |
Silbert et al. | Persistent hyperplastic primary vitreous | |
Schepens et al. | The vitreous and vitreoretinal interface | |
JP4256941B2 (ja) | 眼球の疾患の治療において硝子体液を液化するために使用されるヒアルロニダーゼ含有製剤 | |
Sebag | Vitreous anatomy and pathology | |
Borodic et al. | Peripapillary subretinal neovascularization and serous macular detachment: association with congenital optic nerve pits | |
JP2006523461A (ja) | 羊ヒアルロニダーゼを単離し精製する方法 | |
AU772884B2 (en) | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders | |
JP2004530645A (ja) | 特定の眼疾患の処置方法 | |
MXPA99010495A (en) | Use of hyaluronidase in the manufacture of an ophthalmic preparation for liquefying vitreous humor in the treatment of eye disorders | |
RU2391954C2 (ru) | Способ лечения распространенного и тотального гемофтальма при диабетической ретинопатии | |
Dujić et al. | Juvenile diabetes eye complications and treatment | |
Mishra et al. | Management of Vitreomacular Traction | |
Jin et al. | Efficacy and safety of platelet-rich plasma for acute nonarteritic anterior ischemic optic neuropathy: a prospective cohort study | |
OHLYAN et al. | To evaluate effects of combination of topical 5% Phenylephrine and 0.8% Tropicamide on Pulse Rate and Blood Pressure | |
COHEN | A selected review of retinal research and study | |
Axelsson | Miotic-induced cataract | |
Todorović et al. | Učinak primarne argon laserske trabekuloplastike na sniženje intraokularnog tlaka i kvalitetu života u bolesnika s pseudoeksfolijacijskim glaukomom | |
Williams | Posterior vitreous detachment | |
TW202202168A (zh) | 用於改善玻璃體混濁的組成物及其應用 | |
Steel et al. | Acute bilateral optic disc neovascularization | |
Montero et al. | Cryotherapy and laser for intermediate uveitis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050324 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20080603 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20080903 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081010 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081003 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20081104 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20081215 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20081203 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090127 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090202 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120206 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120206 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130206 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130206 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20140206 Year of fee payment: 5 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |